Verification evidence is still being completed.
PDF / print export
Hoba Therapeutics ApS
Copenhagen, Denmark
- Verified lead
- Torsten M. Madsen
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Non-Opioid Chronic Pain, Sensorineural Hearing Loss, and Peripheral Nervous System Targets
- Review cycle
- 24 April 2026
- Full address
- Ole Maaloes Vej (BioInnovation Institute), 2200 Copenhagen N, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Hoba Therapeutics About page naming Torsten M. Madsen as Chief Executive Officer.
- Editorial note
- Copenhagen non-opioid pain and hearing-loss biotech with named CEO, 23 million EUR Series A, and a clinical lead program HB-086.
Non-Opioid Chronic Pain, Sensorineural Hearing Loss, and Peripheral Nervous System Targets
Public CEO disclosure on company site, Series A financing documentation, BioInnovation Institute-linked address
Copenhagen non-opioid pain and hearing-loss biotech with named CEO, 23 million EUR Series A, and a clinical lead program HB-086.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Copenhagen, Denmark
Hoba Therapeutics ApS
Non-Opioid Chronic Pain, Sensorineural Hearing Loss, and Peripheral Nervous System Targets · Early clinical-stage biotech
Copenhagen non-opioid pain and hearing-loss biotech with named CEO, 23 million EUR Series A, and a clinical lead program HB-086.
- Lead
- Torsten M. Madsen (verified ↗)
- Address
- Ole Maaloes Vej (BioInnovation Institute), 2200 Copenhagen N, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Early clinical-stage biotech
- Capabilities
- Non-Opioid Pain Drug Discovery · Sensorineural Hearing Loss Pipeline · Peripheral Nervous System Targeting
- Founded
- 2018
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Torsten M. Madsen
Chief Executive Officer
Full addressOle Maaloes Vej (BioInnovation Institute), 2200 Copenhagen N, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Bionity company record listing Hoba Therapeutics at Ole Maaloes Vej, Copenhagen.
Open sourceEarly clinical-stage biotech
Copenhagen, Denmark. Non-Opioid Chronic Pain, Sensorineural Hearing Loss, and Peripheral Nervous System Targets. Review completed on 24 Apr 2026.
Danish Medicines Agency and EMA for clinical oversight
Public CEO disclosure on company site, Series A financing documentation, BioInnovation Institute-linked address
Non-Opioid Chronic Pain, Sensorineural Hearing Loss, and Peripheral Nervous System Targets
Copenhagen non-opioid pain and hearing-loss biotech with named CEO, 23 million EUR Series A, and a clinical lead program HB-086.
Editorial note
Hoba Therapeutics is an early clinical-stage neuroscience biotech with a named CEO, a documented Series A of 23 million EUR, and a BioInnovation Institute-linked Copenhagen address.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Non-Opioid Pain Drug Discovery
Sensorineural Hearing Loss Pipeline
Peripheral Nervous System Targeting
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Neuroscience discovery workflow
Clinical trial operations
Partner CDMO supply
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Hoba Therapeutics ApS located?
- Hoba Therapeutics ApS operates from Ole Maaloes Vej (BioInnovation Institute), 2200 Copenhagen N, Denmark, Copenhagen, Denmark.
- Who runs Hoba Therapeutics ApS?
- Hoba Therapeutics ApS is led by Torsten M. Madsen, Chief Executive Officer. Verified 24 Apr 2026.
- What does Hoba Therapeutics ApS do?
- Copenhagen non-opioid pain and hearing-loss biotech with named CEO, 23 million EUR Series A, and a clinical lead program HB-086. Core capabilities: Non-Opioid Pain Drug Discovery, Sensorineural Hearing Loss Pipeline, Peripheral Nervous System Targeting.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.